Gland Pharma Limited is issuing a public health compliance notice under the Drugs Price Control Order 2013 to announce the strategic discontinuation of five major scheduled medical formulations including Acris, Merocide, Pizoglan, and Survec—advising active patients and medical personnel to consult doctors for alternative healthcare prescriptions over the next six to twelve months.